Hence, the oncogenic role of p-BRCA in NSCLC in tumor development and in the prediction of response to treatment remains unclear and testing for BRCA1/2 mutations is not considered to be an integral part of molecular workup in cases of newly diagnosed NSCLC. The gene discussed is BRCA1; the disease is non-small cell lung carcinoma.